News

The TROPION-Lung12 trial uses a circulating tumor DNA assay to preoperatively screen patients with non–small cell lung cancer for eligibility in post-surgical adjuvant treatment regimens.

The FDA updated the fludarabine phosphate injection labeling under Project Renewal, clarifying the dosage for combination therapy and streamlining safety warnings.

Cesar Rodriguez, MD, discussed several key aspects of talquetamab use in the treatment of relapsed/refractory multiple myeloma.

The FDA granted fast track designation to ALE.P02, an antibody-drug conjugate targeting Claudin-1 (CLDN1), for use in patients with advanced/metastatic CLDN1-positive squamous solid tumors.

Noah S. Kalman, MD, MBA, discusses how oncologists can determine the best course of action for the treatment and management of a patient with thyroid cancer.

Barbara O’Brien, MD, discusses the background behind the phase 2 TBCRC049 study investigating the combination of tucatinib, trastuzumab, and capecitabine for the treatment of patients with HER2-positive breast cancer and leptomeningeal metastasis.

The phase 1 INSIGHT-003 trial showed that adding eftilagimod alpha to pembrolizumab and chemotherapy achieved a median overall survival of 32.9 months in metastatic non–small cell lung cancer.

The FDA has approved FoundationOne Liquid CDx as a companion diagnostic for patients with metastatic non–small cell lung cancer with MET exon 14 skipping alterations eligible for tepotinib.

Jaime Merchan, MD, discusses the background and findings from the LITESPARK-013 trial of belzutifan for the treatment of patients with advanced clear cell renal cell carcinoma.

A pivotal phase 2 trial of WU-CART-007, an anti-CD7 CAR T-cell therapy for relapsed/refractory T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma treatment, will begin in 2025.

The FDA-cleared Spectral CT 7500 RT, a detector-based computed tomography radiotherapy solution aimed to enhance radiation therapy with spectral 4DCT imaging.

The ECLIPSE trial, a pivotal, phase 3, multi-center, open-label, randomized clinical study, has met its primary end point in metastatic castration-resistant prostate cancer.

The phase 2 CELLVX-230 trial is assessing the potential of FK-PC101 to prevent prostate cancer recurrence and delay additional treatments post-surgery.

The 22nd Annual Winter Lung Cancer Conference® will explore advances in neoadjuvant/adjuvant therapies. The FDA has approved Obe-cel for R/R B-ALL, and new treatments in SCLC, lurbinectedin and tarlatamab, show promise. Apalutamide tops enzalutamide in real-world data for mCSPC, and LBL-034 gains orphan drug designation for multiple myeloma.

The key secondary end point of overall survival was met in the DREAMM-7 trial of belantamab mafodotin for the treatment of patients with relapsed/refractory multiple myeloma.

Revumenib is now an FDA-approved treatment for adult and pediatric patients with relapsed/refractory KMT2A-rearranged acute leukemia.

Yanghee Woo, MD, discusses the details and lasting impact of the CROSS trial in the treatment of gastroesophageal junction and esophageal cancers.

Patient dosing has begun in a phase 1 trial evaluating QXL138AM, a masked immunocytokine targeting CD138, in advanced solid tumors and multiple myeloma.

The FDA has approved a re-engineered formulation of nilotinib with no mealtime restrictions for adult patients with newly diagnosed Ph-positive CP- and AP-CML, or for those resistant or intolerant to prior therapy, including imatinib.

The FDA has approved the investigational new drug application of AS1986NS for prostate cancer detection and treatment.

A new BLA for datopotamab deruxtecan aims for FDA accelerated approval to treat EGFR-mutated NSCLC based on data from multiple TROPION trials, following FDA feedback.

Yanghee Woo, MD, provides an overview of the CROSS trial which focused on treating patients with gastroesophageal junction cancers.

Nicole Lamanna, MD, discussed some of the ongoing clinical trials evaluating new therapies for patients with chronic lymphocytic leukemia.

At the 42nd Annual Chemotherapy Foundation Symposium, Erin Mulvey, MD, discussed the significant progress being made in the treatment of relapsed or refractory follicular lymphoma.

The SELECT-MDS-1 trial showed no significant complete response rate improvement with tamibarotene plus azacitidine for high-risk myelodysplastic syndrome, leading to the trial being discontinued.

In this episode of Targeted Talks, Douglas Flora, MD, LSSBB, FACCC, discusses the transformative impact of artificial intelligence in oncology.

In an interview with Targeted Oncology, Michael Mauro, MD, delved into the rapidly advancing field of chronic myeloid leukemia treatment.

Ariel Lopez-Chavez, MD, discusses the current approach to managing recurrent small cell lung cancer especially in patients who have progressed after first-line chemotherapy.

A phase 1 trial of pembrolizumab plus denileukin diftitox shows 27% response and 33% clinical benefit in recurrent solid tumors, with manageable toxicity.